{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:36:46Z","timestamp":1789774606480,"version":"4.0.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We investigated whether body mass index (BMI) correlates with distinct outcomes in newly diagnosed acute promyelocytic leukemia (APL). The study population included 144 patients with newly diagnosed and genetically confirmed APL consecutively treated at a single institution. All patients received All-trans retinoic acid and idarubicin according to the GIMEMA protocols AIDA-0493 and AIDA-2000. Outcome estimates according to the BMI were carried out together with multivariable analysis for the risk of relapse and differentiation syndrome. Fifty-four (37.5%) were under\/normal weight (BMI &lt; 25), whereas 90 (62.5%) patients were overweight\/obese (BMI \u2265 25). An increased BMI was associated with older age (P &lt; .0001) and male sex (P = .02). BMI was the most powerful predictor of differentiation syndrome in multivariable analysis (odds ratio = 7.24; 95% CI, 1.50-34; P = .014). After a median follow-up of 6 years, the estimated cumulative incidence of relapse at 5 years was 31.6% (95% CI, 22.7%-43.8%) in overweight\/obese and 11.2% (95% CI, 5.3%-23.8%) in underweight\/normal weight patients (P = .029). Multivariable analysis showed that BMI was an independent predictor of relapse (hazard ratio = 2.45, 95% CI, 1.00-5.99, in overweight\/obese vs under\/normal weight patients, P = .049). An increased BMI at diagnosis is associated with a higher risk of developing differentiation syndrome and disease relapse in APL patients treated with AIDA protocols.<\/jats:p>","DOI":"10.1182\/blood-2011-07-369595","type":"journal-article","created":{"date-parts":[[2011,11,3]],"date-time":"2011-11-03T05:24:01Z","timestamp":1320297841000},"page":"49-54","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":54,"title":["Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols"],"prefix":"10.1182","volume":"119","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mazzarella","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, European Institute of Oncology, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bagnardi","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy;"},{"name":"Department of Statistics, University of Milano-Bicocca, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Disalvatore","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy;"},{"name":"Frontier Science and Technology Research Foundation Southern Europe, Chiasso, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Loglisci","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cimino","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome\u2013Polo Pontino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Testi","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Avvisati","sequence":"additional","affiliation":[{"name":"Hematology Unit, University Campus Bio-Medico, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Petti","sequence":"additional","affiliation":[{"name":"Department of Hematology, IFO, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Minotti","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Latagliata","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giuseppe","family":"Pelicci","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, European Institute of Oncology, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lo-Coco","sequence":"additional","affiliation":[{"name":"Department of Biopathology, University Tor Vergata, Rome, Italy; and"},{"name":"Laboratory of Neuro-Oncohematology, Santa Lucia Foundation, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2019111721305106400_B1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1470-2045(02)00849-5","article-title":"Overweight, obesity, and cancer risk.","volume":"3","author":"Bianchini","year":"2002","journal-title":"Lancet Oncol"},{"issue":"7","key":"2019111721305106400_B2","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.ejca.2008.11.004","article-title":"Overweight, obesity and risk of haematological malignancies: a cohort study of Swedish and Finnish twins.","volume":"45","author":"Soderberg","year":"2009","journal-title":"Eur J Cancer"},{"issue":"17","key":"2019111721305106400_B3","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults.","volume":"348","author":"Calle","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111721305106400_B4","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/ijc.23176","article-title":"Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies.","volume":"122","author":"Larsson","year":"2008","journal-title":"Int J Cancer"},{"issue":"1","key":"2019111721305106400_B5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-009-0512-0","article-title":"The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.","volume":"119","author":"de Azambuja","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2019111721305106400_B6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/0300985809357753","article-title":"Effect of obesity on breast cancer development.","volume":"47","author":"Cleary","year":"2010","journal-title":"Vet Pathol"},{"issue":"5","key":"2019111721305106400_B7","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: from highly fatal to highly curable.","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111721305106400_B8","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood-2008-05-159632","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.","volume":"112","author":"Sanz","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111721305106400_B9","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2009-07-233387","article-title":"Very long-term outcome of acute promyelocytic leukaemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.","volume":"115","author":"Ad\u00e8s","year":"2010","journal-title":"Blood"},{"issue":"18","key":"2019111721305106400_B10","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1182\/blood-2010-08-302950","article-title":"AIDA-0493 protocol for newly diagnosed acute promyelocytic leucemia: very long-term results and role of maintenance.","volume":"117","author":"Avvisati","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111721305106400_B11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2010.32.1067","article-title":"Modern approaches to treating acute promyelocytic leukemia.","volume":"29","author":"Sanz","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111721305106400_B12","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.","volume":"111","author":"de la Serna","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111721305106400_B13","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/sj.leu.2400783","article-title":"Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia.","volume":"11","author":"Estey","year":"1997","journal-title":"Leukemia"},{"issue":"17","key":"2019111721305106400_B14","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1182\/blood-2010-03-276196","article-title":"Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group.","volume":"116","author":"Lo-Coco","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111721305106400_B15","first-page":"1014","article-title":"Molecular remission in PML\/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy.","volume":"90","author":"Mandelli","year":"1997","journal-title":"Blood"},{"issue":"4","key":"2019111721305106400_B16","first-page":"1247","article-title":"Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.","volume":"96","author":"Sanz","year":"2000","journal-title":"Blood"},{"issue":"4","key":"2019111721305106400_B17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/0003-4819-120-4-199402150-00004","article-title":"All trans retinoic acid for acute promyelocytic leukemia: results of the New York Study.","volume":"120","author":"Frankel","year":"1994","journal-title":"Ann Intern Med"},{"issue":"9492","key":"2019111721305106400_B18","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(05)67483-1","article-title":"Obesity.","volume":"366","author":"Haslam","year":"2005","journal-title":"Lancet"},{"key":"2019111721305106400_B19","article-title":"Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation [WHO technical report series 894].","author":"World Health Organization","year":"2000"},{"key":"2019111721305106400_B20","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"key":"2019111721305106400_B21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"5","key":"2019111721305106400_B22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/sim.4780080504","article-title":"Flexible regression models with cubic splines.","volume":"8","author":"Durrleman","year":"1989","journal-title":"Stat Med"},{"issue":"9","key":"2019111721305106400_B23","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.leu.2401126","article-title":"Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia.","volume":"12","author":"Thomas","year":"1998","journal-title":"Leukemia"},{"issue":"5","key":"2019111721305106400_B24","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood.V93.5.1668","article-title":"Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities.","volume":"93","author":"Konopleva","year":"1999","journal-title":"Blood"},{"issue":"5","key":"2019111721305106400_B25","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2003-03-0802","article-title":"PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival.","volume":"103","author":"Tabe","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111721305106400_B26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1017\/S0029665108006976","article-title":"Obesity and cancer.","volume":"67","author":"Pischon","year":"2008","journal-title":"Proc Nutr Soc"},{"issue":"10","key":"2019111721305106400_B27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1055\/s-0029-1241870","article-title":"Obesity and cancer.","volume":"117","author":"Percik","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"4","key":"2019111721305106400_B28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.leukres.2009.09.017","article-title":"High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia.","volume":"34","author":"Jeddi","year":"2010","journal-title":"Leuk Res"},{"issue":"4","key":"2019111721305106400_B29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111721305106400_B30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2005.05595.x","article-title":"Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.","volume":"130","author":"Kuchenbauer","year":"2005","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111721305106400_B31","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/blood.V93.12.4131","article-title":"Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.","volume":"93","author":"Burnett","year":"1999","journal-title":"Blood"},{"issue":"4","key":"2019111721305106400_B32","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/blood.V82.4.1264.1264","article-title":"Acute promyelocytic leukemia: clinical relevance of two major PML-RAR\u03b1 isoforms and detection of minimal residual disease by retrotranscriptase\/polymerase chain reaction to predict relapse.","volume":"82","author":"Huang","year":"1993","journal-title":"Blood"},{"issue":"11","key":"2019111721305106400_B33","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood.V84.11.3843.bloodjournal84113843","article-title":"Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN\/RAR-\u03b1 isoform, and CD13 expression in patients treated with all-trans retinoic acid.","volume":"84","author":"Vahdat","year":"1994","journal-title":"Blood"},{"issue":"3","key":"2019111721305106400_B34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/10428190310001617295","article-title":"Clinico-biological features and prognostic significance of PML\/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.","volume":"45","author":"Gupta","year":"2004","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/1\/49\/1347630\/zh800112000049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/1\/49\/1347630\/zh800112000049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T02:31:06Z","timestamp":1574044266000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/1\/49\/125702\/Increased-BMI-correlates-with-higher-risk-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-07-369595","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,5]]}}}